Exothera
Hanna P. Lesch is currently serving as the Chief Technology Officer at EXOTHERA in Belgium. Prior to this role, she held positions such as Gene Therapy Unit Director at Kuopio Center for Gene and Cell Therapy, Research and Development Director at FinVector Oy, and Research Director at FKD Therapies. She has a strong background in gene therapy, process development of viral vectors, and extensive experience in the field. Hanna has also completed her Doctor of Philosophy in Molecular Medicine from the University of Eastern Finland, where she also obtained her Master's degree in Biotechnology.
This person is not in any offices
Exothera
Exothera is a contract research, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. At Exothera and Univercells, Our mission is to make life-changing therapies available to all. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing. Company number: 0744643660 VAT: BE0744643660